Enanta Pharmaceuticals | ENTA - Cash And Equivalent


Enanta Pharmaceuticals reported $37.44M in Cash and Equivalent for its fiscal quarter ending in December of 2025.





Cash And Equivalent Change Date
AbbVie USD 9.39B 4.16B Mar/2026
Amgen USD 12.04B 2.91B Mar/2026
Anika Therapeutics USD 41.02M 16.46M Mar/2026
Arrowhead Research USD 201.64M 112.94M Dec/2025
AstraZeneca USD 7.56B 1.85B Mar/2026
BioCryst Pharmaceuticals USD 171.59M 164.32M Mar/2026
Biogen USD 3.38B 374.2M Mar/2026
Bristol-Myers Squibb USD 9.57B 635M Mar/2026
Enanta Pharmaceuticals USD 37.44M 5.14M Dec/2025
Gilead Sciences USD 7.56B 234M Dec/2025
GlaxoSmithKline GBP 3.44B 292M Mar/2026
Halozyme Therapeutics USD 309.75M 175.93M Mar/2026
Heron Therapeutics USD 26.12M 2.53M Mar/2026
Immunic USD 186.63M 171.15M Mar/2026
Incyte USD 4.02B 435.22M Mar/2026
Insmed USD 582.19M 71.74M Mar/2026
Ionis Pharmaceuticals USD 1.92B 758M Mar/2026
J&J USD 21.69B 1.98B Mar/2026
Karyopharm Therapeutics USD 60.54M 22.87M Dec/2025
Ligand Pharmaceuticals USD 115.08M 59.85M Mar/2026
Merck USD 5.33B 9.24B Mar/2026
Neurocrine Biosciences USD 266.5M 446.5M Mar/2026
Novartis USD 6.88B 4.56B Mar/2026
Novavax USD 228.36M 12.27M Mar/2026
Pfizer USD 1.7B 561M Mar/2026
PTC Therapeutics USD 833.99M 150.66M Mar/2026
Roche Holding CHF 7.55B 579M Jun/2025
Sarepta Therapeutics USD 464.45M 336.83M Mar/2026
Vertex Pharmaceuticals USD 7.25B 638.6M Mar/2026